Carfilzomib, cyclophosphamide and dexamethasone for newly diagnosed, high-risk myeloma patients not eligible for transplant: a pooled analysis of two studies

Despite remarkable advances in the treatment of multiple myeloma (MM) in the last decades, the prognosis of patients harboring highrisk cytogenetic abnormalities remains dismal as compared to that of standard-risk patients. Proteasome inhibitors have been demonstrated to partially ameliorate the pro...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Haematologica
Hauptverfasser: Mina, Roberto, Bonello, Francesca, Petrucci, Maria Teresa, Liberati, Anna Marina, Conticello, Concetta, Ballanti, Stelvio, Musto, Pellegrino, Olivieri, Attilio, Benevolo, Giulia, Capra, Andrea, Gilestro, Milena, Galieni, Piero, Cavo, Michele, Siniscalchi, Agostina, Palumbo, Antonio, Montefusco, Vittorio, Gaidano, Gianluca, Omedé, Paola, Boccadoro, Mario, Bringhen, Sara
Format: Artigo
Sprache:Inglês
Veröffentlicht: Fondazione Ferrata Storti 2020
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC8018137/
https://ncbi.nlm.nih.gov/pubmed/32107329
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2019.243428
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge